Overexpression of WW domain-containing oxidoreductase WOX1 preferentially induces apoptosis in human glioblastoma cells harboring mutant p53

Biomedicine and Pharmacotherapy

Volumn 66, Issue 6, 2012, Pages 433-438

  Chiang, Ming Fu ^a,b   Yeh, Shu Ting ^a   Liao, Hui Fen ^c   Chang, Nan Shan ^d,e,f   Chen, Yu Jen ^a  

^a MACKAY MEMORIAL HOSPITAL   (Taiwan)

^b TAIPEI MEDICAL UNIVERSITY   (Taiwan)

^c NATIONAL CHIAYI UNIVERSITY   (Taiwan)

^d NATIONAL CHENG KUNG UNIVERSITY   (Taiwan)

^e GUTHRIE RESEARCH INSTITUTE   (United States)

^f State University of New York Upstate Medical University: College of Medicine   (United States)

Author keywords

Apoptosis; Glioblastoma; P53; WOX1

Indexed keywords

CASPASE 3; MUTANT PROTEIN; OXIDOREDUCTASE; PROTEIN P53; TEMOZOLOMIDE; UNCLASSIFIED DRUG; WOX1 PROTEIN;

APOPTOSIS; ARTICLE; CONTROLLED STUDY; DNA FRAGMENTATION; ENZYME ACTIVITY; GLIOBLASTOMA; HUMAN; HUMAN CELL; MITOCHONDRION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; CELL LINE, TUMOR; CELL SHAPE; CELL SURVIVAL; CHROMATIN ASSEMBLY AND DISASSEMBLY; DACARBAZINE; DNA FRAGMENTATION; GLIOBLASTOMA; HUMANS; IN SITU NICK-END LABELING; MEMBRANE POTENTIAL, MITOCHONDRIAL; MOLECULAR TARGETED THERAPY; MUTANT PROTEINS; OXIDOREDUCTASES; PLOIDIES; RECOMBINANT PROTEINS; TUMOR SUPPRESSOR PROTEIN P53; TUMOR SUPPRESSOR PROTEINS; UP-REGULATION;

EID: 84866156432     PISSN: 07533322     EISSN: 19506007     Source Type: Journal    
DOI: 10.1016/j.biopha.2012.03.003     Document Type: Article

References (23)

1. Buckner J.C. Factors influencing survival in high-grade gliomas. Semin Oncol 2003, 30:10-14.
2. Stupp R., Hegi M.E., Mason W.P., van den Bent M.J., Taphoorn M.J., Janzer R.C., et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 2009, 10:459-466.
3. Chang N.S., Hsu L.J., Lin Y.S., Lai F.J., Sheu H.M. WW domain-containing oxidoreductase: a candidate tumor suppressor. Trends Mol Med 2007, 13:12-22.
4. Ried K., Finnis M., Hobson L., Mangelsdorf M., Dayan S., Nancarrow J.K., et al. Common chromosomal fragile site FRA16D sequence: identification of the FOR gene spanning FRA16D and homozygous deletions and translocation breakpoints in cancer cells. Hum Mol Genet 2000, 9:1651-1663.
5. Del Mare S., Salah Z., Aqeilan R.I. WWOX: its genomics, partners, and functions. J Cell Biochem 2009, 108:737-745.
6. Chang N.S., Doherty J., Ensign A., Lewis J., Heath J., Schultz L., et al. Molecular mechanisms underlying WOX1 activation during apoptotic and stress responses. Biochem Pharmacol 2003, 66:1347-1354.
7. Ludes-Meyers J.H., Kil H., Parker-Thornburg J., Kusewitt D.F., Bedford M.T., Aldaz C.M. Generation and characterization of mice carrying a conditional allele of the Wwox tumor suppressor gene. PLoS One 2009, 4:e7775.
8. Donati V., Fontanini G., Dell'Omodarme M., Prati M.C., Nuti S., Lucchi M., et al. WWOX expression in different histologic types and subtypes of non-small cell lung cancer. Clin Cancer Res 2007, 13:884-891.
9. Ishii H., Furukawa Y. Alterations of common chromosome fragile sites in hematopoietic malignancies. Int J Hematol 2004, 79:238-242.
10. Aqeilan R.I., Kuroki T., Pekarsky Y., Albagha O., Trapasso F., Baffa R., et al. Loss of WWOX expression in gastric carcinoma. Clin Cancer Res 2004, 10:3053-3058.
11. Kuroki T., Yendamuri S., Trapasso F., Matsuyama A., Aqeilan R.I., Alder H., et al. The tumor suppressor gene WWOX at FRA16D is involved in pancreatic carcinogenesis. Clin Cancer Res 2004, 10:2459-2465.
12. Aqeilan R.I., Donati V., Gaudio E., Nicoloso M.S., Sundvall M., Korhonen A., et al. Association of Wwox with ErbB4 in breast cancer. Cancer Res 2007, 67:9330-9336.
13. Guler G., Uner A., Guler N., Han S.Y., Iliopoulos D., Hauck W.W., et al. The fragile genes FHIT and WWOX are inactivated coordinately in invasive breast carcinoma. Cancer 2004, 100:1605-1614.
14. Fabbri M., Iliopoulos D., Trapasso F., Aqeilan R.I., Cimmino A., Zanesi N., et al. WWOX gene restoration prevents lung cancer growth in vitro and in vivo. Proc Natl Acad Sci U S A 2005, 102:15611-15616.
15. Nakayama S., Semba S., Maeda N., Aqeilan R.I., Huebner K., Yokozaki H. Role of the WWOX gene, encompassing fragile region FRA16D, in suppression of pancreatic carcinoma cells. Cancer Sci 2008, 99:1370-1376.
16. Hong Q., Sze C.I., Lin S.R., Lee M.H., He R.Y., Schultz L., et al. Complement C1q activates tumor suppressor WWOX to induce apoptosis in prostate cancer cells. PLoS One 2009, 4:e5755.
17. Walker K.K., Levine A.J. Identification of a novel p53 functional domain that is necessary for efficient growth suppression. Proc Natl Acad Sci U S A 1996, 93:15335-15340.
18. Chang N.S., Pratt N., Heath J., Schultz L., Sleve D., Carey G.B., et al. Hyaluronidase induction of a WW domain-containing oxidoreductase that enhances tumor necrosis factor cytotoxicity. J Biol Chem 2001, 276:3361-3370.
19. Chang N.S., Doherty J., Ensign A., Schultz L., Hsu L.J., Hong Q. WOX1 is essential for tumor necrosis factor-, UV light-, staurosporine-, and p53-mediated cell death, and its tyrosine 33-phosphorylated form binds and stabilizes serine 46-phosphorylated p53. J Biol Chem 2005, 280:43100-43108.
20. Gjerset R.A., Turla S.T., Sobol R.E., Scalise J.J., Mercola D., Collins H., et al. Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol Carcinog 1995, 14:275-285.
21. Squatrito M., Brennan C.W., Helmy K., Huse J.T., Petrini J.H., Holland E.C. Loss of ATM/Chk2/p53 pathway components accelerates tumor development and contributes to radiation resistance in gliomas. Cancer Cell 2010, 18:619-629.
22. Shinoura N., Muramatsu Y., Nishimura M., Yoshida Y., Saito A., Yokoyama T., et al. Adenovirus-mediated transfer of p33ING1 with p53 drastically augments apoptosis in gliomas. Cancer Res 1999, 59:5521-5528.
23. Chamberlain M.C. Temozolomide: therapeutic limitations in the treatment of adult high-grade gliomas. Expert Rev Neurother 2010, 10:1537-1544.